[144] Adaptimmune Therapeutics plc American SEC Filing
Form 144 notice for Adaptimmune Therapeutics plc (ADAP): A proposed sale of 13,829,778 American Depositary Receipts is being submitted for sale through J.P. Morgan Securities LLC on or about 08/15/2025 on NASDAQ. The form lists the issuer's total shares outstanding as 1,590,309,546 and reports an aggregate market value for the proposed sale of 981,914. The ADRs were acquired in private placements from the issuer on several dates between 09/23/2014 and 09/05/2018, with recorded quantities for each acquisition and cash as the nature of payment. No securities were reported sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information.
Avviso Form 144 per Adaptimmune Therapeutics plc (ADAP): 脠 stata presentata una proposta di vendita di 13.829.778 American Depositary Receipts tramite J.P. Morgan Securities LLC, con esecuzione prevista intorno al 15/08/2025 sul NASDAQ. Il modulo indica il totale delle azioni in circolazione dell'emittente pari a 1.590.309.546 e riporta un valore di mercato aggregato della proposta di vendita pari a 981.914. Gli ADR sono stati acquisiti in collocamenti privati dall'emittente in diverse date tra il 23/09/2014 e il 05/09/2018, con le quantit脿 registrate per ciascuna acquisizione e il pagamento in contanti. Nei tre mesi precedenti il dichiarante non ha segnalato vendite di titoli. Il dichiarante certifica di non essere a conoscenza di informazioni sfavorevoli materiali non divulgate.
Aviso Formulario 144 para Adaptimmune Therapeutics plc (ADAP): Se ha presentado una propuesta de venta de 13.829.778 American Depositary Receipts a trav茅s de J.P. Morgan Securities LLC, con fecha prevista en torno al 15/08/2025 en el NASDAQ. El formulario indica un total de acciones en circulaci贸n del emisor de 1.590.309.546 y reporta un valor de mercado agregado para la venta propuesta de 981.914. Los ADR se adquirieron en colocaciones privadas del emisor en varias fechas entre el 23/09/2014 y el 05/09/2018, con las cantidades registradas para cada adquisici贸n y pago en efectivo. El declarante no inform贸 ventas de valores en los 煤ltimos tres meses. El declarante certifica que no tiene conocimiento de informaci贸n adversa material no divulgada.
Adaptimmune Therapeutics plc(ADAP)鞐� 雽�頃� Form 144 韱奠: 13,829,778臧滌潣 American Depositary Receipts(ADR)毳� J.P. Morgan Securities LLC毳� 韱淀暣 鞎� 2025-08-15鞐� NASDAQ鞐愳劀 毵り皝頃� 鞓堨爼鞚措澕電� 鞝滌晥鞚� 鞝滌稖霅橃棃鞀惦媹雼�. 頃措嫻 鞏戩嫕鞚� 氚滍枆靷潣 齑� 氚滍枆欤检嫕鞚� 1,590,309,546搿� 旮办灛頃橁碃 鞝滌晥霅� 毵り皝鞚� 齑� 鞁滉皜毳� 981,914搿� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. ADR鞚� 2014-09-23攵赌韯� 2018-09-05旯岇 鞐煬 彀鞐� 瓯胳箿 氚滍枆鞛愳棎 雽�頃� 靷搿� 旆摑霅橃棃鞙茧┌, 臧� 旆摑 鞁滌潣 靾橂焿瓿� 順勱笀 歆�旮夓澊 旮半霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 歆�雮� 3臧滌洈 霃欖晥 鞙犼皜歃濌秾鞚� 毵る弰頃� 氚� 鞐嗢潓鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�.
Avis Formulaire 144 pour Adaptimmune Therapeutics plc (ADAP) : Une proposition de vente de 13 829 778 American Depositary Receipts a 茅t茅 soumise via J.P. Morgan Securities LLC, pour ex茅cution aux alentours du 15/08/2025 sur le NASDAQ. Le formulaire indique le nombre total d'actions en circulation de l'茅metteur 脿 1 590 309 546 et rapporte une valeur marchande agr茅g茅e de la vente propos茅e de 981 914. Les ADR ont 茅t茅 acquis lors de placements priv茅s aupr猫s de l'茅metteur 脿 plusieurs dates entre le 23/09/2014 et le 05/09/2018, avec les quantit茅s enregistr茅es pour chaque acquisition et un paiement en esp猫ces. Le d茅clarant n'a signal茅 aucune vente de titres au cours des trois derniers mois. Il certifie ne pas 锚tre au courant d'informations d茅favorables majeures non divulgu茅es.
Formular 144-Mitteilung f眉r Adaptimmune Therapeutics plc (ADAP): Ein geplanter Verkauf von 13.829.778 American Depositary Receipts wird 眉ber J.P. Morgan Securities LLC mit voraussichtlichem Ausf眉hrungsdatum um den 15.08.2025 an der NASDAQ eingereicht. Das Formular gibt die insgesamt ausstehenden Aktien des Emittenten mit 1.590.309.546 an und meldet einen aggregierten Marktwert des geplanten Verkaufs von 981.914. Die ADRs wurden in Privatplatzierungen des Emittenten an mehreren Daten zwischen dem 23.09.2014 und dem 05.09.2018 erworben; die jeweils erworbenen St眉ckzahlen und Barzahlungen sind verzeichnet. Der Meldende gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben. Er best盲tigt, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
- Brokered sale through reputable broker (J.P. Morgan Securities LLC) which suggests orderly execution
- Detailed acquisition history provided, including dates and quantities from 2014 to 2018
- Proposed sale of 13,829,778 ADRs increases potential supply of shares on NASDAQ
- Aggregate market value reported (981,914) lacks explicit currency/unit context within this text
Insights
TL;DR: Routine Form 144 filing disclosing a proposed sale of ADRs through a broker with acquisition history provided; no recent sales reported.
The filing documents a proposed brokered sale of 13,829,778 ADRs on NASDAQ via J.P. Morgan, including detailed acquisition dates and quantities from multiple private placements between 2014 and 2018. The form properly includes the filers representation about material undisclosed information and indicates no securities sold in the past three months. From a compliance perspective, the submission contains the core elements required for Rule 144 notices: class of securities, broker, intended sale date, outstanding shares, acquisition history, and signature/representation language. The aggregate market value field is reported as 981,914, which should be verified for currency/units in the underlying filing record.
TL;DR: Disclosure indicates a sizable ADR block offered through a major broker, with multi-year holding history鈥攖ypical institutional/insider liquidity action.
The schedule shows the ADRs were acquired in multiple private placements from the issuer with cash payment, suggesting the holder obtained the securities from early financings. The planned use of J.P. Morgan Securities LLC to execute a sale on or about 08/15/2025 is consistent with standard market execution for a large block. The filing does not provide price guidance, tranche timing, or whether the sale will be structured to comply with volume limitations under Rule 144 beyond the notice itself. For investors, the document is a disclosure of potential supply; it does not by itself quantify immediate market impact.
Avviso Form 144 per Adaptimmune Therapeutics plc (ADAP): 脠 stata presentata una proposta di vendita di 13.829.778 American Depositary Receipts tramite J.P. Morgan Securities LLC, con esecuzione prevista intorno al 15/08/2025 sul NASDAQ. Il modulo indica il totale delle azioni in circolazione dell'emittente pari a 1.590.309.546 e riporta un valore di mercato aggregato della proposta di vendita pari a 981.914. Gli ADR sono stati acquisiti in collocamenti privati dall'emittente in diverse date tra il 23/09/2014 e il 05/09/2018, con le quantit脿 registrate per ciascuna acquisizione e il pagamento in contanti. Nei tre mesi precedenti il dichiarante non ha segnalato vendite di titoli. Il dichiarante certifica di non essere a conoscenza di informazioni sfavorevoli materiali non divulgate.
Aviso Formulario 144 para Adaptimmune Therapeutics plc (ADAP): Se ha presentado una propuesta de venta de 13.829.778 American Depositary Receipts a trav茅s de J.P. Morgan Securities LLC, con fecha prevista en torno al 15/08/2025 en el NASDAQ. El formulario indica un total de acciones en circulaci贸n del emisor de 1.590.309.546 y reporta un valor de mercado agregado para la venta propuesta de 981.914. Los ADR se adquirieron en colocaciones privadas del emisor en varias fechas entre el 23/09/2014 y el 05/09/2018, con las cantidades registradas para cada adquisici贸n y pago en efectivo. El declarante no inform贸 ventas de valores en los 煤ltimos tres meses. El declarante certifica que no tiene conocimiento de informaci贸n adversa material no divulgada.
Adaptimmune Therapeutics plc(ADAP)鞐� 雽�頃� Form 144 韱奠: 13,829,778臧滌潣 American Depositary Receipts(ADR)毳� J.P. Morgan Securities LLC毳� 韱淀暣 鞎� 2025-08-15鞐� NASDAQ鞐愳劀 毵り皝頃� 鞓堨爼鞚措澕電� 鞝滌晥鞚� 鞝滌稖霅橃棃鞀惦媹雼�. 頃措嫻 鞏戩嫕鞚� 氚滍枆靷潣 齑� 氚滍枆欤检嫕鞚� 1,590,309,546搿� 旮办灛頃橁碃 鞝滌晥霅� 毵り皝鞚� 齑� 鞁滉皜毳� 981,914搿� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. ADR鞚� 2014-09-23攵赌韯� 2018-09-05旯岇 鞐煬 彀鞐� 瓯胳箿 氚滍枆鞛愳棎 雽�頃� 靷搿� 旆摑霅橃棃鞙茧┌, 臧� 旆摑 鞁滌潣 靾橂焿瓿� 順勱笀 歆�旮夓澊 旮半霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 歆�雮� 3臧滌洈 霃欖晥 鞙犼皜歃濌秾鞚� 毵る弰頃� 氚� 鞐嗢潓鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�.
Avis Formulaire 144 pour Adaptimmune Therapeutics plc (ADAP) : Une proposition de vente de 13 829 778 American Depositary Receipts a 茅t茅 soumise via J.P. Morgan Securities LLC, pour ex茅cution aux alentours du 15/08/2025 sur le NASDAQ. Le formulaire indique le nombre total d'actions en circulation de l'茅metteur 脿 1 590 309 546 et rapporte une valeur marchande agr茅g茅e de la vente propos茅e de 981 914. Les ADR ont 茅t茅 acquis lors de placements priv茅s aupr猫s de l'茅metteur 脿 plusieurs dates entre le 23/09/2014 et le 05/09/2018, avec les quantit茅s enregistr茅es pour chaque acquisition et un paiement en esp猫ces. Le d茅clarant n'a signal茅 aucune vente de titres au cours des trois derniers mois. Il certifie ne pas 锚tre au courant d'informations d茅favorables majeures non divulgu茅es.
Formular 144-Mitteilung f眉r Adaptimmune Therapeutics plc (ADAP): Ein geplanter Verkauf von 13.829.778 American Depositary Receipts wird 眉ber J.P. Morgan Securities LLC mit voraussichtlichem Ausf眉hrungsdatum um den 15.08.2025 an der NASDAQ eingereicht. Das Formular gibt die insgesamt ausstehenden Aktien des Emittenten mit 1.590.309.546 an und meldet einen aggregierten Marktwert des geplanten Verkaufs von 981.914. Die ADRs wurden in Privatplatzierungen des Emittenten an mehreren Daten zwischen dem 23.09.2014 und dem 05.09.2018 erworben; die jeweils erworbenen St眉ckzahlen und Barzahlungen sind verzeichnet. Der Meldende gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben. Er best盲tigt, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What does the Form 144 filed for ADAP disclose?
How many ADAP shares are outstanding according to this filing?
When and how were the ADRs being offered acquired?
Did the filer sell any securities in the past three months?
Does the filing indicate any undisclosed material information about ADAP?
